Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: A phase II trial

A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer

“…In this study, the pneumonitis and esophagitis rates were acceptable and the incidence of grades 3 and 4 toxicity was comparable to other studies. The 7% grades 1 and 2 pneumonitis rate is better than that of commonly used regimen like taxane plus a platinum agent [27][28][29], and the 12% grade 3 esophagitis rate is the same or better than in most studies [27][28][29][30][31]. Although these figures were not excessively high, esophagitis and functional decline were the main reasons which led to dose interruptions during concurrent chemoradiotherapy.…”

Does Response to Induction Chemotherapy Predict Survival for Locally Advanced Non–Small-Cell Lung Cancer? Secondary Analysis of RTOG 8804/8808

“…Local failure was also the most common site of initial failure in the CALGB 9431 and Spanish trials (11,13), with the patterns of failure not yet reported for the Phase III CALGB trial. The incidence of local relapse reported in other cohorts after CCRT alone was comparable to the results of these analyses (4,16).…”

“…Another Phase II study from the CALGB (CALGB 9534) found a 15.1-month median survival of unresectable Stage III NSCLC patients receiving induction carboplatin and paclitaxel and then CCRT (12). A multi-institution, Phase II trial in Spain showed a 52% response rate to induction carboplatin and paclitaxel and a median survival of 15 months in Stage IIIB NSCLC patients receiving ICT followed by concurrent paclitaxel and 60 Gy RT (13). Although these results were encouraging compared with the historical median survival results for these patients (14)(15)(16)(17) and comparable with the outcomes of patients treated with ICT followed by CCRT in RTOG 8804/8808, recently reported results from the follow-up Phase III trial (CALGB 39801), despite a similar response to ICT (31% PR+regres-sion), did not show a survival benefit for patients receiving induction carboplatin and paclitaxel before CCRT vs. those treated with CCRT alone (18).…”

Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer

“…Among the third-generation regimens, a weekly paclitaxel plus carboplatin (PC) regimen is one of the most commonly used regimens, and there is considerable interest in the combination of PC with TRT for the treatment of locally advanced NSCLC. Since the 1990s, several clinical trials [2,[4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] have demonstrated a mean survival time (MST) ranging from 14 to 35 months for the PE regimen plus TRT and a MST of 12-28 months for the weekly PC regimen plus TRT in unresectable IIIA/IIIB NSCLC.…”